Global adoption Hemex Health has an established Gazelle Hb Variant Test platform with usage in more than 40 countries through partnerships like Case, indicating substantial international market traction and potential for expanding distribution agreements, channel partnerships, and regional deployments.

FDA recognition The recent FDA Breakthrough Device Designation for Gazelle Hb Variant Test signals strong regulatory credibility and faster time-to-market opportunities, which can be leveraged to pursue pilots with larger health systems and national programs seeking rapid deployment of advanced diagnostics.

Affordable frontline tech The company emphasizes low-cost, easy-to-use diagnostic solutions targeted at the developing world, presenting clear sales plays with government health ministries, public health networks, and NGO collaborations focused on scalable, affordable screening for hemoglobin disorders and related conditions.

Strategic collaborations Recent partnerships with Case and Tata Elxsi to develop portable diagnostics for malaria and sickle-cell disease underscore opportunities for co-development, OEM-like licensing, and co-marketing ventures to broaden product reach in high-need markets.

Growth and recognition Award momentum and a growing revenue footprint, with revenue in the mid-teens millions and recognized awards for growth and healthtech leadership, provide talking points for outreach to impact-focused funds, health authorities, and corporate partners seeking proven, scalable diagnostics solutions.